


EXPLORER-HCM

#ESCCongress



AMERICAN
COLLEGE of
CARDIOLOGY

Trial Description: Patients with hypertrophic cardiomyopathy were randomized to mavacamten 5 mg daily versus placebo for 30 weeks.



RESULTS

- Primary endpoint, ≥ 1.5 ml/kg/min increase in pVO₂ with ≥ 1 NYHA class improvement or ≥ 3.0 ml/kg/min increase in pVO₂ with no worsening of NYHA class at 30 weeks, occurred in 37% of the mavacamten group vs. 17% of the placebo group (p = 0.0005)

CONCLUSIONS

- Among patients with hypertrophic obstructive cardiomyopathy, mavacamten was superior to placebo
- Mavacamten improved functional capacity and health status

Olivotto I, et al. *Lancet* 2020;396:759-69